⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
European Commission Approves KEYTRUDA ® (pembrolizumab) Plus Padcev ® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
businesswire.com
MRK
Bio-Based Solvents Take Center Stage at CHEMUK
accessnewswire.com
MRK
Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets
businesswire.com
MRK
HelixIntel Expands HelixCMMS with Fleet Management, Bringing Vehicles, Drivers, and Maintenance Into One Platform
globenewswire.com
MRK
NGG
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
businesswire.com
MRK
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
businesswire.com
MRK
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
globenewswire.com
ABBV
ALNY
ASTL
AZN
BIIB
BMY
CSL
LLY
GILD
GSK
MRK
NVS
NVO
PFE
REGN
SNY
SUN
TEVA
UPST
VRTX
Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design
globenewswire.com
PFE
NVS
MRK
JNJ
Alger Russell Innovation Index Updates for Second Quarter 2026
prnewswire.com
ADBE
DOCS
DOX
GNTX
META
MRK
RBLX
TRMB
XYZ
Z
ZS
CORT
DV
GTM
ILMN
NTAP
OKTA
P
QCOM
TDC
TWLO
ZM
Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
prnewswire.com
MRK